论文部分内容阅读
1商品名Femara2化学名1－[双（4-氰基苯基）甲基]-1，2，4-三唑3开发与上市厂商（瑞士）Ciba制药公司开发，1996年在英国首先上市。4药效分类芳香化酶抑制剂5药理约有1／3以上的乳腺癌依赖于雌激素的刺激而继续发展。研究抑制雌激素生物合成对这个领域内药物开发是十分必要的。
1 Product name Femara2 Chemical name 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole 3 Developed and marketed by a manufacturer (Switzerland) developed by Ciba Pharmaceuticals and first listed in the United Kingdom in 1996. 4 Pharmacodynamic classification Aromatase inhibitor 5 Pharmacology About 1/3 or more of breast cancers rely on estrogen stimulation and continue to develop. Research on the inhibition of estrogen biosynthesis is essential for drug development in this area.